Skip to content

Effect of Nightly Versus Prn Sildenafil on Early Return of Erectile Function Following Laparoscopic Radical Prostatectomy

Effect of Nightly Versus Prn Sildenafil on Early Return of Erectile Function Following Nerve-Sparing Laparoscopic Radical Prostatectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00511498
Enrollment
100
Registered
2007-08-06
Start date
2006-03-31
Completion date
2008-10-31
Last updated
2008-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Laparoscopic Radical Prostatectomy, Nightly sildenafil

Brief summary

The ability of sildenafil to aid in the return of erections after nerve-sparing radical prostatectomy has been established. Patients who had either one or both neurovascular bundles spared demonstrated dramatically better responses to as needed sildenafil than those that did not, and a positive erectile response to sildenafil was only seen in patients in whom at least one NVB was spared. This study has been designed to determine if sildenafil taken nightly works better than sildenafil on as as needed basis for the return of erectile function. The investigators hypothesis is that sildenafil taken nightly promotes a more rapid return of erectile function after nerve-sparing laparoscopic radical prostatectomy.

Interventions

DRUGSildenafil

50 mg daily at bedtime

Sponsors

Johns Hopkins University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

1. Male sex 2. Age \< 65 3. IIEF erectile function domain score \> 26 (out of 30 points possible for this subscale) 4. Steady sexual partner 5. Untreated prostate cancer TNM stage \< cT2bNxMx (cT1a, cT1b, cT1c, cT2a) and Gleason grade \< 8. 6. Willingness to participate in a clinical trial as manifested by informed consent 7. Actually undergo nerve-sparing LRP surgery

Exclusion criteria

1. Not fulfilling all of the criteria for entry above 2. Any prior prostate cancer treatment (radiation, hormonal deprivation, chemotherapy) 3. Contraindication to sildenafil (e.g. nitrates, hypersensitivity) 4. Existing PDE5 inhibitor requirement for functional erection (e.g. for intercourse) preoperatively 5. Obstructive sleep apnea

Design outcomes

Primary

MeasureTime frame
IIEF score13 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026